van Vught Lonneke A, Wiewel Maryse A, Klein Klouwenberg Peter M C, Hoogendijk Arie J, Scicluna Brendon P, Ong David S Y, Cremer Olaf L, Horn Janneke, Bonten Marc M J, Schultz Marcus J, van der Poll Tom
1Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2The Center for Infection and Immunity, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 4Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands. 5Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 6Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 7Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Crit Care Med. 2016 Jul;44(7):1338-46. doi: 10.1097/CCM.0000000000001650.
To investigate whether admission hyperglycemia is associated with the presentation and/or outcome of sepsis, what the influence of hyperglycemia is on key host responses to sepsis, and whether hyperglycemia differentially affects patients with diabetes mellitus.
A substudy of a prospective observational cohort study was conducted in the intensive care of two tertiary hospitals between January 2011 and July 2013.
Of all consecutive critically ill sepsis patients, admission glucose was used to stratify patients in euglycemia (71-140 mg/dL), mild hyperglycemia (141-199 mg/dL), and severe hyperglycemia (≥ 200 mg/dL), and patients with hypoglycemia were excluded. Fifteen plasma biomarkers providing insight in key host responses implicated in sepsis pathogenesis were measured on admission.
Of 987 sepsis patients with admission glucose levels greater than 70 mg/dL, 519 (52.6%) had normal glucose levels, 267 (27.1%) had mild, and 201 (20.4%) severe hyperglycemia. Admission hyperglycemia was accompanied by mitigated alterations in plasma host response biomarker levels indicative of activation of the cytokine network, the vascular endothelium, and the coagulation system in patients without a history of diabetes. Severe, but not mild, admission hyperglycemia was associated with increased 30-day mortality (adjusted hazard ratio, 1.66 [95% CI, 1.24-2.23]), in both patients without diabetes (adjusted hazard ratio, 1.65 [95% CI, 1.12-2.42]) and with diabetes (adjusted hazard ratio, 1.91 [95% CI, 1.01-3.62]).
Admission hyperglycemia is associated with adverse outcome of sepsis irrespective of the presence or absence of preexisting diabetes by a mechanism unrelated to exaggerated inflammation or coagulation.
探讨入院时高血糖是否与脓毒症的表现和/或结局相关,高血糖对宿主对脓毒症关键反应的影响,以及高血糖是否对糖尿病患者有不同影响。
2011年1月至2013年7月间,在两家三级医院的重症监护室进行了一项前瞻性观察队列研究的子研究。
在所有连续的重症脓毒症患者中,入院血糖用于将患者分为正常血糖(71-140mg/dL)、轻度高血糖(141-199mg/dL)和重度高血糖(≥200mg/dL),排除低血糖患者。入院时测量了15种血浆生物标志物,以了解脓毒症发病机制中关键的宿主反应。
在987例入院血糖水平大于70mg/dL的脓毒症患者中,519例(52.6%)血糖水平正常,267例(27.1%)轻度高血糖,201例(20.4%)重度高血糖。入院时高血糖伴有血浆宿主反应生物标志物水平变化减轻,这表明在无糖尿病病史的患者中细胞因子网络、血管内皮和凝血系统被激活。重度而非轻度入院时高血糖与30天死亡率增加相关(校正风险比,1.66[95%CI,1.24-2.23]),在无糖尿病患者(校正风险比,1.65[95%CI,1.12-2.42])和糖尿病患者(校正风险比,1.91[95%CI,1.01-3.62])中均如此。
入院时高血糖与脓毒症的不良结局相关,无论是否存在糖尿病,其机制与炎症或凝血过度无关。